FLEX ADJUVANT PUBLICATIONS & ABSTRACTS
Clinical evidence from FLEX
Evidence / Adjuvant / FLEX
Prediction of Chemotherapy Benefit by MammaPrint in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
Title: Prediction of Chemotherapy Benefit by MammaPrint® in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data Authors: Adam Brufsky*, Kent Hoskins, Henry Conter, Pond Kelemen, Mehran Habibi, Laila Samian, Robert Maganini, Rakshanda Rahman, Laura Lee, Eduardo Dias, Regina Hampton, Beth Seiling, Cynthia Osborne, Read More
Association of MammaPrint With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition
Title: Association of MammaPrint® With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition Background: Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have become a first-line targeted treatment in combination with endocrine therapy for patients with recurring HR+HER2- breast cancer (BC) and have recently been added to the Read More
MammaPrint 3-year outcomes with CT with/without anthracycline
ASCO 2024, #511 Presenter: O'Shaughnessy et al.
Read MorePrediction of chemotherapy benefit by MammaPrint®, Audeh et al., Miami Breast 2024
Miami Breast 2024, Poster 29 Authors: Audeh et al.
Read MoreRacial Disparities in HR+HER2- ESBC, Reid et al., SABCS 2023 Abstract
SABCS 2023, PO1-28-01 Authors: Sonya Reid et al.
Read MoreRacial Disparities in Latin American Patients-FLEX, Mazo Canola et al., SABCS 2023 Abstract
SABCS 2023, PS18-04 Authors: Marcela Mazo Canola et al.
Read MoreResponse Predictive Subtypes in Lobular Tumors-FLEX, Mukhtar et al., SABCS 2023 Abstract
SABCS 2023, PO4-02-03 Authors: Mukhtar et al.
Read More
